463 related articles for article (PubMed ID: 23286859)
1. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?
Papatheodoridis GV
Liver Int; 2013 Feb; 33 Suppl 1():151-6. PubMed ID: 23286859
[TBL] [Abstract][Full Text] [Related]
2. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
Papatheodoridis GV
Liver Int; 2011 Jan; 31 Suppl 1():95-103. PubMed ID: 21205145
[TBL] [Abstract][Full Text] [Related]
3. Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue.
Ma H; Jia J
Liver Int; 2013 Feb; 33 Suppl 1():133-6. PubMed ID: 23286857
[TBL] [Abstract][Full Text] [Related]
4. HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
Buti M
Liver Int; 2014 Feb; 34 Suppl 1():108-11. PubMed ID: 24373086
[TBL] [Abstract][Full Text] [Related]
5. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.
Dusheiko G
Liver Int; 2013 Feb; 33 Suppl 1():137-50. PubMed ID: 23286858
[TBL] [Abstract][Full Text] [Related]
6. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
7. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
[TBL] [Abstract][Full Text] [Related]
8. Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?
Vlachogiannakos J; Papatheodoridis GV
Liver Int; 2015 Jan; 35 Suppl 1():100-6. PubMed ID: 25529094
[TBL] [Abstract][Full Text] [Related]
9. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
Viganò M; Mangia G; Lampertico P
Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
[TBL] [Abstract][Full Text] [Related]
10. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
Vlachogiannakos J; Papatheodoridis GV
Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic hepatitis B: Evolution over two decades.
Yuen MF; Lai CL
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
[TBL] [Abstract][Full Text] [Related]
12. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
Lampertico P; Viganò M; Colombo M
Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
[TBL] [Abstract][Full Text] [Related]
13. Current developments in nucleoside/nucleotide analogues for hepatitis B.
Lo AO; Wong GL
Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):607-22. PubMed ID: 24787673
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
Buster EH; Schalm SW; Janssen HL
Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
[TBL] [Abstract][Full Text] [Related]
15. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
Kao JH
Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
[TBL] [Abstract][Full Text] [Related]
16. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
18. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833
[TBL] [Abstract][Full Text] [Related]
20. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
Viganò M; Invernizzi F; Lampertico P
Liver Int; 2015 Jan; 35 Suppl 1():107-13. PubMed ID: 25529095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]